Fosun Pharma Reports 2025 Annual Results Highlighting Innovation and Global Expansion
Fosun Pharma, a leading global pharmaceutical and healthcare company, announced its annual operating results for 2025 on March 24, 2026. Marking a year of significant advancement, the company recorded total operating revenue of RMB 41.662 billion, up by 1.45% from the previous year. This growth was largely fueled by innovation in its pharmaceutical offerings and an increasing presence in international markets. Notably, revenue generated from innovative drugs soared to RMB 9.893 billion, reflecting a remarkable 29.59% increase compared to the prior year, which illustrates the company's strength in research and development (R&D). Meanwhile, the international revenue surged to RMB 12.977 billion, representing a 14.87% uptick year-on-year.
Net profit attributable to shareholders of Fosun Pharma demonstrated a significant increase, reaching RMB 3.371 billion, which is a 21.69% rise from last year. The recurring net profit figure was RMB 2.34 billion, experiencing a marginal 1.12% increase year-on-year. The net cash flow from operating activities also showed a healthy growth of 16.45%, totaling RMB 5.213 billion, indicating a solid financial foundation for the company moving forward.
Innovation as the Growth Engine
Among the different sectors of Fosun Pharma’s operations, revenue from innovative drugs has become increasingly pivotal, accounting for 33.16% of the pharmaceutical business revenue. The company has demonstrated its commitment to R&D, investing RMB 5.913 billion in total R&D activities, a 6.46% increase from the preceding year. Specifically, the investments in innovative pharmaceuticals reached RMB 4.303 billion, rising by 15.98% year-on-year and comprising 80.26% of the total pharmaceutical R&D funding.
These substantial investments have yielded impressive results in 2025. Fosun Pharma obtained marketing approval for 16 indications across 7 innovative drugs both in China and abroad. Alongside this, the company had 6 innovative drug candidates accepted for marketing applications, while nearly 40 clinical trials for innovative drugs received regulatory approval. The successful introduction of 5 new innovative drugs into the 2025 National Reimbursement Drug List (NRDL) is set to enhance patient access significantly, echoing the company’s commitment to advancing healthcare solutions.
Strengthening the Clinical Pipeline
Fosun Pharma’s strategy emphasizes developing innovative drugs, particularly in oncology, immune inflammation, and neurodegenerative diseases. In oncology, the approved small-molecule innovative drug Fumaining® (luvometinib Tablet) was a notable achievement, filling treatment gaps for rare tumors in China. Moreover, the anti-PD-1 monoclonal antibody, Serplulimab Injection, secured marketing approval in Europe, thus enhancing Fosun’s international footprint. The company has made strides in diversifying its therapeutic pipeline, achieving significant milestones across several core products.
In immune inflammation, the new treatment option for chronic kidney disease patients, Wantile (Tenapanor Hydrochloride Tablets), reflects Fosun Pharma’s progress in addressing chronic illnesses. The company is also innovating in neurodegenerative diseases, launching Opicapone Capsules for Parkinson's disease and expanding its innovative product pipeline with the addition of Sodium Oligomannate Capsules for Alzheimer's disease.
Globalization and Resource Integration
Fosun Pharma’s globalization efforts have led to a strategic transformation focusing on systemic global integration. The company’s international revenue accounted for 31.15% of total revenue, showcasing significant growth from international operations compared to the previous year. The organization has also established a robust global R&D and production alignment, achieving milestone payments exceeding US$3.8 billion through out-licensing arrangements.
The success of Fosun Pharma's global strategy is visible in its marketing network expansion across over 40 countries, coupled with deep-rooted collaborations with international entities. Furthermore, Fosun has maintained its strong ESG performance, earning recognition from global authorities, including an upgrade to its MSCI ESG rating to 'AA', confirming its commitment to sustainability and corporate responsibility.
As stated by Chen Yuqing, Chairman of Fosun Pharma, the company is committed to deepening its engagement in core therapeutic areas while continuously fostering innovation and leveraging digital intelligence across its operations. As it looks to the future, Fosun Pharma aims to create long-term value for its shareholders and enhance the accessibility of quality healthcare solutions for patients worldwide.
Net profit attributable to shareholders of Fosun Pharma demonstrated a significant increase, reaching RMB 3.371 billion, which is a 21.69% rise from last year. The recurring net profit figure was RMB 2.34 billion, experiencing a marginal 1.12% increase year-on-year. The net cash flow from operating activities also showed a healthy growth of 16.45%, totaling RMB 5.213 billion, indicating a solid financial foundation for the company moving forward.
Innovation as the Growth Engine
Among the different sectors of Fosun Pharma’s operations, revenue from innovative drugs has become increasingly pivotal, accounting for 33.16% of the pharmaceutical business revenue. The company has demonstrated its commitment to R&D, investing RMB 5.913 billion in total R&D activities, a 6.46% increase from the preceding year. Specifically, the investments in innovative pharmaceuticals reached RMB 4.303 billion, rising by 15.98% year-on-year and comprising 80.26% of the total pharmaceutical R&D funding.
These substantial investments have yielded impressive results in 2025. Fosun Pharma obtained marketing approval for 16 indications across 7 innovative drugs both in China and abroad. Alongside this, the company had 6 innovative drug candidates accepted for marketing applications, while nearly 40 clinical trials for innovative drugs received regulatory approval. The successful introduction of 5 new innovative drugs into the 2025 National Reimbursement Drug List (NRDL) is set to enhance patient access significantly, echoing the company’s commitment to advancing healthcare solutions.
Strengthening the Clinical Pipeline
Fosun Pharma’s strategy emphasizes developing innovative drugs, particularly in oncology, immune inflammation, and neurodegenerative diseases. In oncology, the approved small-molecule innovative drug Fumaining® (luvometinib Tablet) was a notable achievement, filling treatment gaps for rare tumors in China. Moreover, the anti-PD-1 monoclonal antibody, Serplulimab Injection, secured marketing approval in Europe, thus enhancing Fosun’s international footprint. The company has made strides in diversifying its therapeutic pipeline, achieving significant milestones across several core products.
In immune inflammation, the new treatment option for chronic kidney disease patients, Wantile (Tenapanor Hydrochloride Tablets), reflects Fosun Pharma’s progress in addressing chronic illnesses. The company is also innovating in neurodegenerative diseases, launching Opicapone Capsules for Parkinson's disease and expanding its innovative product pipeline with the addition of Sodium Oligomannate Capsules for Alzheimer's disease.
Globalization and Resource Integration
Fosun Pharma’s globalization efforts have led to a strategic transformation focusing on systemic global integration. The company’s international revenue accounted for 31.15% of total revenue, showcasing significant growth from international operations compared to the previous year. The organization has also established a robust global R&D and production alignment, achieving milestone payments exceeding US$3.8 billion through out-licensing arrangements.
The success of Fosun Pharma's global strategy is visible in its marketing network expansion across over 40 countries, coupled with deep-rooted collaborations with international entities. Furthermore, Fosun has maintained its strong ESG performance, earning recognition from global authorities, including an upgrade to its MSCI ESG rating to 'AA', confirming its commitment to sustainability and corporate responsibility.
As stated by Chen Yuqing, Chairman of Fosun Pharma, the company is committed to deepening its engagement in core therapeutic areas while continuously fostering innovation and leveraging digital intelligence across its operations. As it looks to the future, Fosun Pharma aims to create long-term value for its shareholders and enhance the accessibility of quality healthcare solutions for patients worldwide.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.